{"id":5173,"date":"2015-06-01T10:41:52","date_gmt":"2015-06-01T14:41:52","guid":{"rendered":"http:\/\/geiselmed.dartmouth.edu\/news\/?p=5173"},"modified":"2015-06-02T10:46:51","modified_gmt":"2015-06-02T14:46:51","slug":"immunotherapy-the-big-new-hope-for-cancer-treatment","status":"publish","type":"post","link":"https:\/\/geiselmed.dartmouth.edu\/news\/2015\/immunotherapy-the-big-new-hope-for-cancer-treatment\/","title":{"rendered":"Immunotherapy: the Big New Hope for Cancer Treatment"},"content":{"rendered":"<p><em><strong>The Guardian<\/strong><\/em> - This article mentions Dartmouth\u2019s Geisel School of Medicine in an article about the overall impact of a cancer immunotherapy clinical trial on melanoma patients. The article also notes\u00a0that the two drugs used in the trial, ipilimumab and nivolumab, were created by the biotech firm called Medarex founded by immunologists from Geisel. The small company was bought by the pharma giant Bristol-Myers Squibb and the following year, Bristol-Myers Squibb announced the first major trial results of ipilimumab. <a href=\"http:\/\/www.theguardian.com\/science\/2015\/jun\/01\/immunotherapy-the-big-new-hope-for-cancer-treatment\" target=\"_blank\">Read more...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p><b><i>The Guardian<\/i><\/b> &#8211; This article mentions Dartmouth\u2019s Geisel School of Medicine in an article about the overall impact of a cancer immunotherapy clinical trial on melanoma patients, and that the two drugs used in the trial, ipilimumab and nivolumab, were created by the biotech firm called Medarex founded by immunologists from Geisel.<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5],"tags":[19,25],"class_list":["post-5173","post","type-post","status-publish","format-standard","hentry","category-in-the-news","tag-cancer","tag-immunology","author-15"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p4r3h1-1lr","_links":{"self":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/5173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/comments?post=5173"}],"version-history":[{"count":1,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/5173\/revisions"}],"predecessor-version":[{"id":5174,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/5173\/revisions\/5174"}],"wp:attachment":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/media?parent=5173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/categories?post=5173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/tags?post=5173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}